PineBridge Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

PineBridge Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,551	Closed	-$568K	–	497
2025 Q4	$568K	Buy	9,551 +1,056	+12%	+$57.5K	﹤0.01%	470
2025 Q3	$460K	Sell	8,495 -26,095	-75%	-$1.49M	﹤0.01%	495
2025 Q2	$1.9M	Buy	34,590 +16,922	+96%	+$996K	0.02%	433
2025 Q1	$1.25M	Sell	17,668 -36,435	-67%	-$2.45M	0.01%	464
2024 Q4	$3.56M	Sell	54,103 -2,314	-4%	-$155K	0.03%	378
2024 Q3	$3.97M	Buy	56,417 +36,295	+180%	+$3.03M	0.03%	352
2024 Q2	$1.66M	Sell	20,122 -10,456	-34%	-$870K	0.01%	395
2024 Q1	$2.67M	Buy	30,578 +7,389	+32%	+$661K	0.02%	394
2023 Q4	$2.24M	Buy	23,189 +5,830	+34%	+$516K	0.02%	363
2023 Q3	$1.54M	Buy	+17,359	New	+$1.54M	0.02%	396

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PineBridge Investments's BMRN Position: Q1 2026 in Review

PineBridge Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 9,551 shares — an estimated $568K sold.

PineBridge Investments first reported a position in BMRN in Q3 2023 and held it in 10 quarters. The position peaked at $3.97M in Q3 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

PineBridge Investments reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
PineBridge Investments sold 9,551 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $568K.
PineBridge Investments first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 10 quarters.
PineBridge Investments's BioMarin Pharmaceuticals position peaked at $3.97M in Q3 2024.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on PineBridge Investments's 13F filing for Q1 2026, filed 14 May 2026.